

ALLERGAN INC  
Form 8-K  
October 14, 2003

Table of Contents

---

**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**  
**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities and Exchange Act of 1934**

**Date of Report** (Date of earliest event reported):  
**October 13, 2003**

**ALLERGAN, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**1-10269**  
(Commission File  
Number)

**95-1622442**  
(IRS Employer  
Identification Number)

**2525 Dupont Drive**  
**Irvine, California**  
(Address of principal executive  
offices)

**92612**  
(Zip Code)

**(714) 246-4500**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On October 14, 2003, Allergan, Inc., a Delaware corporation ( Allergan ), announced the execution of an Agreement and Plan of Merger, dated as of October 13, 2003 (the Merger Agreement ), by and among Allergan, Wilson Acquisition, Inc., a California corporation and wholly-owned subsidiary of Allergan ( Merger Sub ), and Oculex Pharmaceuticals, Inc., a California corporation ( Oculex ). Pursuant to the Merger Agreement, Merger Sub will merge with and into Oculex, with Oculex surviving and becoming a wholly-owned subsidiary of Allergan.

A copy of Allergan s press release dated October 14, 2003 announcing the execution of the Merger Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) Exhibits

99.1 Allergan, Inc. Press Release dated October 14, 2003.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLERGAN, INC.

Date: October 14, 2003

By:           /s/ Eric K. Brandt

Name: Eric K. Brandt  
Title: Corporate Vice President and Chief  
Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Allergan, Inc. Press Release dated October 14, 2003.